Zynga–Zynga had a breakeven second quarter, matching Street estimates, but the online game developer saw revenues fall short of consensus forecasts. It also slashed its guidance for the full year because of delays in several of its new games.
CBS–The broadcast giant beat estimates by seven cents with second quarter profit of 78 cents per share, excluding certain items. However, its revenue fell short, hurt by the loss of broadcast rights to the NCAA college basketball tournament, which is now broadcast by TBS. CBS also announced a dividend hike to 15 cents per share from 12 cents, and doubled its share buyback program to $6 billion.
SolarCity–The Elon Musk-backed company reported a smaller-than-expected loss for its latest quarter, citing "unexpected demand" for its solar panels.
Lululemon–Founder Chip Wilson is selling half his 27 percent stake in the company to private equity firm Advent International for $845 million. The two sides have agreed to avoid waging a proxy war, pushing back the possibility of a hostile merger or acquisition transaction.
Nvidia–The company scored a two cent beat with second quarter profit of 22 cents per share, and the graphics chipmaker also gave a current quarter forecast above analyst estimates. Nvidia is increasing sales of chips designed for automobiles and other new markets, although the majority of its business is still in personal computers.
Monster Beverage– The energy drink maker earned 81 cents per share for the second quarter, six cents above estimates, but revenue was shy of forecasts.
Lionsgate–The film studio beat estimates by nine cents with fiscal first quarter profit of 27 cents per share, excluding certain items. Revenue, however, was well short of estimates, with the movie studio releasing only two movies during the quarter compared to three the year before. The profit increase came amid a significant drop in expenses.
Tekmira Pharmaceuticals–The drug maker said the FDA has modified a hold put on its experimental drug to treat the Ebola virus, which allows the company to make the drug known as TKM-Ebola available to patients.
—By CNBC's Peter Schacknow
Questions? Comments? Email us at firstname.lastname@example.org